IPSEN (OTCMKTS:IPSEY) Shares Gap Up – Time to Buy?

IPSEN (OTCMKTS:IPSEY)’s stock price gapped up before the market opened on Wednesday . The stock had previously closed at $44.07, but opened at $47.11. IPSEN shares last traded at $47.11, with a volume of 2,108 shares traded.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. HC Wainwright reissued a “buy” rating on shares of IPSEN in a research report on Tuesday, June 30th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of IPSEN in a report on Thursday, May 14th. Finally, Zacks Research upgraded shares of IPSEN to a “hold” rating in a research note on Friday, May 29th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold”.

IPSEN Stock Performance

The company has a 50-day moving average price of $46.28 and a two-hundred day moving average price of $45.15.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).